High-Level Overview

Project teams can improve results by recognizing that the future is inevitably uncertain and that by creating flexible designs they can adapt to eventualities. This approach enables them to take advantage of new opportunities and avoid harmful losses. Designers of complex, long-lasting projects--such as communication networks, power plants, or hospitals--must learn to abandon fixed specifications and narrow forecasts. They need to avoid the "flaw of averages," the conceptual pitfall that traps so many designs in underperformance. Failure to allow for changing circumstances risks leaving significant value untapped. This book is a guide for creating and implementing value-enhancing flexibility in design. It will be an essential resource for all participants in the development and operation of technological systems: designers, managers, financial analysts, investors, regulators, and academics. The book provides a high-level overview of why flexibility in design is needed to deliver significantly increased value. It describes in detail methods to identify, select, and implement useful flexibility. The book is unique in that it explicitly recognizes that future outcomes are uncertain. It thus presents forecasting, analysis, and evaluation tools especially suited to this reality. Appendixes provide expanded explanations of concepts and analytic tools.

[1]  K. J. Craik,et al.  The nature of explanation , 1944 .

[2]  A. Turing The chemical basis of morphogenesis , 1952, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.

[3]  H. Simon,et al.  Rational choice and the structure of the environment. , 1956, Psychological review.

[4]  R. W. White Motivation reconsidered: the concept of competence. , 1959, Psychological review.

[5]  H. Simon,et al.  Motivational and emotional controls of cognition. , 1967, Psychological review.

[6]  G. Johansson Visual perception of biological motion and a model for its analysis , 1973 .

[7]  T. Dexter,et al.  In vitro duplication and ‘cure’ of haemopoietic defects in genetically anaemic mice , 1977, Nature.

[8]  Rodney A. Brooks,et al.  A Robust Layered Control Syste For A Mobile Robot , 2022 .

[9]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.

[10]  V. Broudy,et al.  Stem cell factor and hematopoiesis. , 1997, Blood.

[11]  Alan Bundy,et al.  On Automating Diagrammatic Proofs of Arithmetic Arguments , 1999, J. Log. Lang. Inf..

[12]  T. Shallice,et al.  CONTENTION SCHEDULING AND THE CONTROL OF ROUTINE ACTIVITIES , 2000, Cognitive neuropsychology.

[13]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[14]  G. Mcmahon,et al.  Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. , 2000, The Journal of investigative dermatology.

[15]  Kenji Nakamura,et al.  Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis , 2000, Oncogene.

[16]  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[17]  Aaron Sloman,et al.  Evolvable Biologically Plausible Visual Architectures , 2001, BMVC.

[18]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[19]  Daniel Polani,et al.  Meaningful Information, Sensor Evolution, and the Temporal Horizon of Embodied Organisms , 2002 .

[20]  B. Druker,et al.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Demetri,et al.  Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.

[22]  C. Der,et al.  Ras Family Signaling: Therapeutic Targeting , 2002, Cancer biology & therapy.

[23]  N. Pryer,et al.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.

[24]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Van Cutsem,et al.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Adolph Learning to learn in the development of action , 2005 .

[28]  E. Jablonka,et al.  Evolution in Four Dimensions: Genetic, Epigenetic, Behavioral, and Symbolic Variation in the History of Life , 2005 .

[29]  J. Fletcher,et al.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Bokemeyer,et al.  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.

[31]  M. Boden,et al.  Mind As Machine: A History of Cognitive Science Two-Volume Set , 2006 .

[32]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[33]  S. Harnad Symbol grounding problem , 1991, Scholarpedia.

[34]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Baccarani,et al.  Imatinib mesylate in the treatment of hematologic malignancies , 2007, Expert opinion on biological therapy.

[36]  K. Owzar,et al.  Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .

[37]  P. Neven,et al.  A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy , 2008, Breast Cancer Research and Treatment.

[38]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  John McCarthy The well-designed child , 2008, Artif. Intell..

[40]  D. Dennett,et al.  The Extended Phenotype: The Long Reach of the Gene , 2008 .

[41]  J. Fletcher,et al.  Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma , 2008, Clinical Cancer Research.

[42]  C. Antonescu,et al.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. D. Van den Abbeele,et al.  Major response to imatinib mesylate in KIT-mutated melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Aaron Sloman,et al.  Architectures, Architecture-Schemas, And The New Science of Mind. 1 , 2008 .

[45]  F. Craig,et al.  Flow cytometric immunophenotyping for hematologic neoplasms. , 2008, Blood.

[46]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[47]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[48]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[49]  H. Kantarjian,et al.  Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. , 2009, Leukemia research.

[50]  M. Heinrich,et al.  Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.

[51]  C. Antonescu,et al.  Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. , 2010 .

[52]  M. Tsao,et al.  Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer , 2010, Cancer.

[53]  C. Horak,et al.  Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[55]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[56]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[57]  Takashi Ikegami,et al.  Chemical Basis for Minimal Cognition , 2010, Artificial Life.

[58]  C. Der,et al.  Inhibition of Ras for cancer treatment: the search continues. , 2011, Future medicinal chemistry.

[59]  M. Heinrich,et al.  Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.

[60]  J. Blay A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. , 2011, Cancer treatment reviews.

[61]  K. O'Byrne,et al.  Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. , 2011, The Lancet. Oncology.

[62]  M. Kris,et al.  A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  F. Cappuzzo,et al.  Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  D. Sargent,et al.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.

[65]  M. Heslin,et al.  Soft Tissue Sarcoma, Version 1.2021 Featured Updates to the NCCN Guidelines , 2022 .

[66]  Carlos Gershenson,et al.  Living is Information Processing: From Molecules to Global Systems , 2012, Acta Biotheoretica.